Zita Garate

As an oncology medical expert at Roche Pharma and a current MBA candidate at IESE, I possess a unique blend of medical expertise and business acumen that sets me apart as an ideal candidate for evaluating biotechnology investment opportunities. Here’s how my medical background plays a crucial role in this role:

Deep Understanding of Oncology: With extensive experience in the field of oncology, I have developed a comprehensive understanding of the disease landscape, including current treatment modalities, emerging therapies, and unmet medical needs. This expertise enables me to evaluate the scientific and clinical potential of biotechnological innovations in the context of cancer care.
Clinical Insight: As a medical expert, I have a strong clinical foundation, encompassing knowledge of disease pathology, treatment protocols, and patient management. This expertise allows me to critically analyze scientific data, clinical trial outcomes, and real-world evidence to assess the efficacy and safety of potential biotech investments in oncology.
Market Dynamics and Competitive Landscape: Working closely with healthcare professionals and being involved in the pharmaceutical industry, I have gained a comprehensive understanding of the oncology market and the competitive landscape. I can leverage this knowledge to evaluate the market potential, competitive positioning, and commercial viability of biotech investment opportunities, considering factors such as target patient populations, reimbursement landscape, and market trends.
Regulatory and Compliance Understanding: In the medical field, compliance with regulatory requirements is paramount. I possess knowledge of the regulatory landscape and the challenges associated with obtaining approvals for new therapies. This understanding allows me to assess the regulatory risks and hurdles that biotech investments may face, ensuring compliance with applicable regulations.
Scientific Due Diligence: I can assess the quality of scientific data, evaluate the strength of preclinical and clinical evidence, and identify potential red flags or gaps in research, providing stakeholders with a comprehensive evaluation of the technology’s potential.
By combining my medical expertise with my ongoing MBA education, I bring a unique perspective to the evaluation of biotechnology investment opportunities. My ability to assess scientific validity, clinical potential, market dynamics, regulatory compliance, and effectively communicate findings positions me as a valuable asset in supporting informed investment decisions within the biotech sector.